April 23, 2007 — Using actual US practice patterns and dosing, epoetin alfa (Epogen; peg-EPO therapy) effectively maintains hemoglobin (Hb) levels in hemodialysis patients, according to a presentation ...

Epoetin Alfa Treatment Results in Clinically Significant Improvements in Quality of Life in Anemic Cancer Patients When Referenced to the General Population. If you have the appropriate software ...

Chemoendocrine Therapy for Premenopausal Women With Axillary Lymph Node–Positive, Steroid Hormone Receptor–Positive Breast Cancer: Results From INT 0101 (E5188) Eligible patients were randomly ...

Please provide your email address to receive an email when new articles are posted on . Significantly more patients who received luspatercept vs. epoetin alfa achieved the study’s primary endpoint of ...

The US Food and Drug Administration (FDA) on Tuesday approved the first biosimilar to Amgen’s blockbuster Epogen/Procrit (epoetin alfa), bringing the total number of biosimilars approved by the agency ...

Dec. 9, 2004 -- The U.S. Food and Drug Administration (FDA) and Ortho Biotech Products warned healthcare professionals via letter of important information regarding the safe dosing of epoetin alfa ...

Pegmolesatide appears as effective as epoetin alfa and can be administered at longer intervals. Monthly subcutaneous pegmolesatide maintains hemoglobin as effectively as conventional epoetin alfa in ...

CHICAGO -- Patients with transfusion-dependent, low-risk myelodysplastic syndromes (MDS) needed significantly fewer transfusions when treated with luspatercept (Reblozyl) for anemia compared with the ...

Reblozyl treatment in patients with anemia from lower-risk myelodysplastic syndromes achieved a greater independence from red blood cell transfusions compared with treatment with epoetin alfa.

In people with myelodysplastic neoplasms (MDS), a usually benign form of chronic lymphocytic leukemia, the body produces too few functional blood cells. Affected individuals suffer from anemia—a lack ...